About Lexogen

lexogen_building

Lexogen is a biotech company with unique proprietary expression profiling technologies that enable detailed analysis of the complete transcriptome as well as individual full length RNAs of interest.

Lexogen was founded in 2007 with the support of both private capital and public funds. Lexogen is supported by the Austrian Research Promotion Agency FFG, the Austria Wirtschaftsservice AWS, INiTS and the Wirtschaftsagentur Wien.

Lexogen is based at the Vienna BioCenter in Vienna, Austria, and has a subsidiary in New Hampshire, USA. 50% of Lexogen employees work in R&D.

VBC-Logo

Using our website is subject of our Privacy Policy.

AWS_logo   FFG_logo   INITS_logo   WWFF_logo

History

February 2019

Release of CORALL Total RNA-Seq Library Prep Kit

December 2018

Upgrade TeloPrime Full-Length cDNA Amplification Kit V2

May 2018

Release of UMI Second Strand Synthesis Module for QuantSeq FWD (Illumina, Read 1)

Upgrade of i5 Unique Dual Indexing Add-on Kit for QuantSeq/SENSE (5001-5096)

July 2018

We are providing Services for Small RNA-Seq, QuantSeq for SLAMseq RNA, and SPLIT RNA Extraction

February 2017

Release of QuantSeq 3’ mRNA-Seq Library Prep Kit (FWD) HT for Illumina

March 2017

Release of RNA-Seq service for generation of QuantSeq 3’ mRNA-Seq libraries, multiplexed sequencing, and data analysis

June 2017

Release of SIRV Set 2 (Iso Mix E0) and 3 (Iso Mix E0 / ERCC)

August 2017

Release of Small RNA-Seq Library Prep Kit

September 2017

Release of SLAMseq Metabolic RNA-Seq Kit

October 2017

Release of SLAMdunk SLAMdunk data analysis for SLAMseq integrated on the Bluebee® platform

November 2017

Data Analysis pipeline for QuantSeq 3’ Library Prep is implemented in Partek® Flow® software

December 2017

Release of new Globin Block Modules for QuantSeq Kits

June 2016

CLC Plug-in “Mix-Square Transcript Quantification”

August 2016

Upgrade RiboCop rRNA Depletion Kit V1.2 (Human/Mouse/Rat)  

Special User Guide for SENSE Total RNA-Seq for FFPE samples

October 2016

Integrated QuantSeq 3’mRNA-Seq Data Analysis Pipeline on the Bluebee Genomics Platform

Upgrade QuantSeq-Flex Targeted RNA-Seq Library Prep Kit V2  

December 2016

Release of the i5 Dual Indexing Add-on Kit for QuantSeq/SENSE

March 2014

Release of QuantSeq 3’ mRNA-Seq Library Prep Kit  

The QuantSeq kit was developed in collaboration with a research institute to meet the demand for a cost-efficient RNA-Seq library preparation method for gene expression analysis by only counting the 3’ end of transcripts.

April 2014

Foundation of Lexogen, Inc. in the US

To be closer to our customers in the USA, enabling overnight delivery on most orders, a subsidiary, Lexogen, Inc.,  was established in New Hampshire in April 2014 as a distribution center.

June 2014

Release of SENSE Total RNA-Seq Library Prep Kit  

September 2014

Release TeloPrime Full-Length cDNA Amplification Kit  

October 2014

Upgrade SENSE mRNA-Seq Library Prep Kit V2  

February 2013

Release of SENSE mRNA-Seq Library Prep Kit

Lexogen has developed a fast, easy and fragmentation-free RNA-Seq library prep kit based on its proprietary strand-displacement stop/ligation technology, yielding libraries with an exceptional strand-specificity.

August 2013

Release of SPLIT RNA Extraction Kit  

Lexogen has, since the start of the company, put a lot of effort into optimizing extraction protocols for the isolation of high quality RNA without any genomic DNA contamination. After the protocol was successfully shared with some customers, efforts were made to put all the know how into a kit.

September 2013

Innovation and employment subsidy by WAFF

The WAFF (Vienna Employment Promotion Fund) supports small and medium-sized companies in Vienna with the implementation of innovation projects and funded Lexogen for the development of the Mix2 software and the SIRVs.

January 2012

1 year FFG grant and innovation voucher

June 2011

Relocation to the Vienna BioCenter

Due to the rapid growth and expansion of the company, Lexogen decided to move to a new place at the Vienna BioCenter in Vienna, Austria, which is the current location of Lexogen’s headquarter, R&D unit and kit production. The company occupies about 850m of area on two floors; more than quadruple the space of the previous location.
VBC-Logo

October 2011

Seed-Financing by AWS

The Austria Wirtschaftsservice Gesellschaft mbH (aws) is the Austrian federal promotional bank. It assists in the foundation and development of innovative companies in the high-tech field and Lexogen acquired seed-financing by the agency.

3 years FFG grant and innovation voucher

The company received funding by the Austrian Research Promotion Agency (FFG) for the development of the SQUARE technology. The FFG is the national funding institution for applied research and development in Austria.

August 2007

Foundation of Lexogen GmbH by Alexander Seitz

The company was founded in August 2007 by Dr. Alexander Seitz with the support of INiTS (Innovation into Business) incubator, having the first employee starting work in October 2007. Lexogen´s first facility was located in a campus in Southern Vienna (Liesing), Austria, where the company stayed until May 2011.

Mission

Lexogen’s mission is to develop innovative technologies that will allow to resolve complexity of the transcriptome - one of the most enigmatic and exciting areas in biology.

Grasshopper1

What is so intriguing about the transcriptome?

Grasshoppers are gentle creatures with brilliant green color and mild temper who mostly enjoy their solitude and live in good harmony with neighbors in the environment. But the other brood, the locust, forms huge swarms, darkens the sky, and greedily devours whatever is on their way, sometimes scaring people and frowning the eyebrows of farmers.

What is fascinating is that these two creatures are actually one species, and they share exactly the same genetic information stored in the form of DNA. Under a certain condition, the grasshoppers turn their color into light brown, their legs become short and spiky, and the wings grow to adapt to cover the long distance of swarm travel, becoming one of the most greedy and aggressive populations on earth.

desertlocust

You don’t need to go far away into the jungle of Africa to see such examples, because even in the human body we can observe similar things, like cancer cells which originate from healthy cells with identical genetic information in DNA. What contributes the most to this Dr. Jekyll and Mr. Hyde process is the RNA, or transcription of genomes, which is called transcriptome.

The transcriptome has long been considered as a key for answering many of the questions in genetics, biology and medicine, extending far beyond central dogma. However its applications have been limited due to technical difficulties, and not much was known about it until recent advancements in the Next Generation Sequencing (NGS) technology. Thanks to NGS, we expect to have a much larger amount of RNA data than what we have accumulated so far in the history of biology.

We at Lexogen are dedicated to this important and exciting field of transcriptome analysis. We are providers of innovative solutions for transcriptome research, and these are already serving scientists all over the world in their passion for pursuit of science and our fight against diseases.

Testimonials

“We have been extensively using the FWD QuantSeq protocol for over a year on a wide variety of sample inputs and levels of quality. It has become our go-to protocol for all transcriptome exploration projects. We like the ease of the workflow and the consistency of the results combined with significantly lower library construction costs compared to Illumina, Clontech and NuGEN. Most impressive are the results for samples with low RINs. We have a recent example of one project that included both high quality and very degraded RNA samples with RINs as low as 1. We used RNA inputs between 10 and 40 ng and sequenced to the depth of about 13 M reads/sample. Resulting gene detection rates were 13 K in the lowest RIN samples. The average across the entire set was 14.2 K. We are now evaluating QuanSeq on a set of RNA samples originated from FFPE material and looking forward to switching over from the Illumina Access protocol.”
Zarema Arbieva, Director, Core Genomics Facility, University of Illinois at Chicago, USA
“I am most pleased the SPLIT kit showed an unbelievable superiority in extracting a lot of RNA from such tedious samples as freshly isolated microglia cells, in comparison to other commercially available kits tried so far! Not only a lot… but also very pure. I am astonished and pleased! I tried the 3 extractions and all of them had more RNA than I could have ever hoped for! This solves 2 years of experimental problems!”
Daniele Mattei, Postdoctoral Researcher, Institute for Pharmacology and Toxicology, University of Zurich – Vetsuisse, Switzerland
“Using the QuantSeq 3´ mRNA-Seq library prep kits, we were able to multiplex >40 samples per sequencing lane and obtain between 2 to 5 million reads per sample. This enabled us to analyze numerous different strains with various exosome and roadblocking factors inactivated, showing that inactivating roadblocks shifted the window of NNS termination downstream.”
Kevin Roy, Postdoctoral Scholar, Lars Steinmetz Lab, Department of Genetics Stanford University School of Medicine, USA
“I was able to isolate more RNA, and of significantly better quality, using the split RNA kit than I have been able to with any other RNA extraction protocol I so far when extracting RNA from P. infestans sporangia and zoospores.”
Sean Patev, Department of Plant Pathology and Plant-Microbe Biology, Cornell University, USA
“Lexogen has developed a cutting edge, fast and efficient RNA-seq library prep kit. The Lexogen SENSE kit enabled our lab to generate high quality RNA-seq data with no previous experience.”
Matt Thomson, Faculty Fellow, Center for Systems and Synthetic Biology, University of California, San Francisco, USA
“With the Lexogen SENSE kit, we were able to rapidly sequence seventeen different samples of neural development. The SENSE kit has provided us with a wealth of high quality sequencing data with a fast and easy protocol. The people at Lexogen take great pride in their product and it shows through their customer service. They have helped us along the way to make sure we get the library we need.”
Jade Mcpherson, Staff Research Associate III, Cellular and Molecular Pharmacology, University of California, San Francisco, USA
“Lexogen SENSE technology allowed precise detection of known fusion genes and antisense chimeric transcripts from RNA-seq data. Additional effective support from Lexogen team contributed significantly to novel discoveries of chimeras in the transcriptome analysis of cancer cells.”
Konstantin Okonechnikov, Postdoc, DKFZ German Cancer Research Center, Heidelberg, Germany
“We have used the QuantSeq 3′ mRNA-Seq library prep kit for generating over 2000 libraries. Preparing 96 samples at a time is easy and can be done in one day. We multiplexed 48 samples on a HiSeq lane and thereby obtained 3 million reads per sample on average. Using this shallow sequencing approach, we were highly impressed by the quality of the data and robustness of the method.”
Bianca Gapp, PhD student, Ludwig Institute for Cancer Research, Oxford, UK
“To compare gene expression measures between 3’-RNA-seq and RNA-seq technologies, we used data from a subset of 20 samples that were previously used in a RNA-seq study of feed efficiency. The correlation of the log10(fold-change) for gene expression (high- vs. low-feed efficiency birds) between these two methods was 0.90. In conclusion, 3’-RNA-seq is a cost effective method amenable to global gene expression studies at population-level, e.g., expression QTL (eQTL) mapping. Also, it allows for accurate detection of the 3’-end of transcripts, enabling verification of the current gene model annotations and global characterization of alternative polyadenylation.”
Behnam Abasht, Assistant Professor, University of Delaware, USA
“We have successfully used the Lexogen QuantSeq FWD kit for the preparation of RNAseq libraries over the last year. The kit provides us with a highly cost effective and reliable, fast solution to generate RNAseq libraries that we subsequently use to assess gene expression levels and most importantly to rapidly compile and assess alternative cleavage and polyadenylation profiles. QuantSeq is a cornerstone for our RNAseq based research, in particular as multiplexing allows us to combine it with cost effective sequencing on the Ion Torrent platform.”
André Furger, Associate Professor, Chromosomal and RNA Biology, Department of Biochemistry, University of Oxford, UK
“With Lexogen Poly(A) Selection kit I was able to isolate reasonable amount of polyadenylated RNA with no trace of rRNA contamination. I see great advantages of this kit in clear-cut protocol and quite low starting concentration of total RNA that you can easily scale-up based on chosen downstream application. The other thing that should be appreciated is Lexogen customer service that provides you with very high level of support.”
Květoslava Brožinová, Research Technician, Research Group: ERA Chair – RNA and Immunity, CEITEC, Brno, Czech Republic
“Using the Lexogen strand-specific RNAseq kit enabled us to generate multiple libraries for massively parallel sequencing in a matter of a few days. The protocol is very detailed, concise and straightforward, and consistently results in high quality material for Illumina sequencing. Analysis of the RNA libraries found good coverage of transcripts across an expression range of five logs. Additionally, we observed enrichment in the expression of expected transcripts under our experimental conditions, with an average CV of less than 5% in biological replicates within the top half of expressed transcripts. The strand specificity of the libraries was excellent, at around an estimated 99.9%, based on the distribution of strandedness for annotated genes. From this analysis we conclude that some 20% of transcripts are directly associated with significant anti-sense transcription, providing a rich source of interesting biological challenges.”
Iryna Charapitsa, Institute of Molecular Biology, Mainz, Germany

Workplace

Want to work for us?

For detailed information about our open positions and application process, please visit our Careers page.